MILLIPLEX^® 人循环癌症生物标志物磁珠板3 - 癌症多重检测

Circulating cancer biomarkers give insight beyond intracellular oncogenesis and into how the body responds to the presence of a tumor, the dysregulation of homeostasis, and the relationship between a tumor and its environment. Multianalyte panels have become essential tools that enable researchers to measure cancer biomarkers simultaneously, teasing out these relationships and applying them to understand tumor biology.

MILLIPLEX^® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 8 analytes in human serum, plasma, and cell culture supernatants.

Analytes included: Cathepsin D, Ferritin, Fibroblast Activation Protein (FAP), Galectin-3, IGFBP3, Melanoma Inhibitory Activty Protein (MIA), Myeloperoxidase (MPO), Sex Hormone Binding Globulin (SHGB)

Note: When IGFBP3 is included in the assay, a larger sample dilution is required. The SHBG Standard was calibrated against WHO standard 08/266 and 250 ng/mL standard was equivalent to 25 nM of WHO standard.

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

通过在此面板中选择可用的分析物来设计多重试剂盒。

Luminex is a registered trademark of Luminex Corporation

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

xMAP is a registered trademark of Luminex Corp

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:

By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.